READ-ONLY DIGITIZATION RESULT
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
J Clin Oncol · 2025-Dec-20 · PMID 41037766
Panel C提取完成待 EXE 对齐验证
overall survival
FIG 2. Kaplan-Meier estimates of (A) duration of complete response, (B) centrally assessed PFS, and (C) OS in the primary analysis (intent-to-treat population). GemOx, gemcitabine plus oxaliplatin; Mosun, mosunetuzumab; NE, not estimable; OS, overall survival; PFS, progression-free survival; Pola, polatuzumab vedotin; R, rituximab.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T19:38:09+00:00 |